pyrazines has been researched along with Coronary Artery Disease in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scheen, AJ | 1 |
| Bond, SJ; Dutka, DP; Hoole, SP; Kydd, AC; McCormick, LM; Read, PA; Ring, LS | 1 |
| Inden, Y; Ishii, H; Ishikawa, S; Koyasu, M; Murohara, T; Shimano, M; Takemoto, K; Uchikawa, T; Watarai, M | 1 |
| Dutka, DP; Heck, PM; Hoole, SP; Khan, FZ; Read, PA | 1 |
| Akiyama, E; Fujiwara, Y; Izumiya, Y; Jinnouchi, H; Kaikita, K; Kim-Mitsuyama, S; Konishi, M; Kurokawa, H; Maeda, H; Matsubara, J; Matsui, K; Nakamura, T; Nozaki, T; Ogawa, H; Ohba, K; Sugamura, K; Sugiyama, S; Sumida, H; Takeya, M | 1 |
| Murohara, T | 1 |
| Akiyama, E; Fujisue, K; Hokimoto, S; Iwashita, S; Jinnouchi, H; Kaikita, K; Kurokawa, H; Maeda, H; Matsubara, J; Ogawa, H; Ohba, K; Sugiyama, S; Yamamoto, E | 1 |
| Satoh, K | 1 |
| Bax, JJ; Boersma, E; Kam, BL; Krenning, EP; Poldermans, D; Rambaldi, R; Reijs, AE; Rietveld, T; Roelandt, JR; Valkema, R | 1 |
| Bax, JJ; Bountioukos, MA; Elhendy, A; Krenning, EP; Poldermans, D; Roelandt, JR; Schinkel, AF; Valkema, R; van Domburg, RT; Vourvouri, EC | 1 |
1 review(s) available for pyrazines and Coronary Artery Disease
| Article | Year |
|---|---|
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2013 |
4 trial(s) available for pyrazines and Coronary Artery Disease
| Article | Year |
|---|---|
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography, Doppler; Echocardiography, Stress; Electrocardiography; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Heart Ventricles; Humans; Male; Myocardial Ischemia; Pilot Projects; Pyrazines; Sitagliptin Phosphate; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Dysfunction, Left | 2014 |
Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Carotid Arteries; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Male; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Tunica Intima; Ultrasonography | 2014 |
Feasibility and image quality of dual-isotope SPECT using 18F-FDG and (99m)Tc-tetrofosmin after acipimox administration.
Topics: Administration, Oral; Chronic Disease; Coronary Artery Disease; Echocardiography; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart; Humans; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Pyrazines; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Ventricular Dysfunction, Left | 2003 |
Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability.
Topics: Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Male; Middle Aged; Pyrazines; Radionuclide Imaging; Radiopharmaceuticals; Ventricular Dysfunction, Left | 2003 |
5 other study(ies) available for pyrazines and Coronary Artery Disease
| Article | Year |
|---|---|
DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
Topics: Coronary Artery Disease; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography, Stress; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Myocardial Stunning; Pilot Projects; Pyrazines; Reproducibility of Results; Sitagliptin Phosphate; Triazoles; Ventricular Dysfunction, Left | 2010 |
A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Cells, Cultured; Coronary Artery Disease; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection.
Topics: Animals; Apolipoproteins E; Coronary Artery Disease; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Humans; Pyrazines; Sitagliptin Phosphate; Triazoles | 2012 |
Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Chi-Square Distribution; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Inflammation Mediators; Linear Models; Logistic Models; Male; Manometry; Middle Aged; Multivariate Analysis; Odds Ratio; Peripheral Arterial Disease; Pyrazines; Risk Factors; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles | 2013 |
Dipeptidyl peptidase-4 inhibitors--emerging player for vascular protection.
Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Endothelium, Vascular; Female; Humans; Male; Peripheral Arterial Disease; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |